跳至主要内容
临床试验/NCT02184065
NCT02184065已完成不适用

Clinical and Therapeutic Evaluation of Meloxicam in Mexican Patients With Rheumatic Diseases

Boehringer Ingelheim0 个研究点目标入组 22,639 人开始时间: 2004年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
22,639
主要终点
Medical global evaluation on a 4-point scale

研究概览

简要总结

Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age of 12 or older and rheumatologic disease

排除标准

  • Hypersensitivity to meloxicam
  • Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS)
  • History of asthma, angioedema or urticaria secondary to NSAIDS
  • Pregnancy or lactation
  • Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure

研究组 & 干预措施

Meloxicam

干预措施: Meloxicam (Drug)

结局指标

主要结局

Medical global evaluation on a 4-point scale

时间窗: 30 and 90 days

Intensity of symptoms at rest evaluated with a 4-point scale

时间窗: 30 and 90 days

Intensity of symptoms during movement evaluated with a 4-point scale

时间窗: 30 and 90 days

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验